
Edwards Lifesciences Corp company profile
$107.11−0.04%Close 16 Nov 2026 · Market value $61.54B
About Edwards Lifesciences Corp
Edwards Lifesciences Corporation develops and sells medical technologies for treating structural heart disease, with a focus on heart valves. Its portfolio spans transcatheter therapies and surgical products for the aortic, mitral, tricuspid and pulmonic valves. Product groups include Transcatheter Aortic Valve Replacement (TAVR), Transcatheter Mitral and Tricuspid Therapies (TMTT), and Surgical Structural Heart. The company sells primarily to hospitals, cardiac surgeons and interventional cardiologists, through direct sales forces and independent distributors. In 2025, 58% of net sales were in the United States and 42% outside it, with sales in approximately 100 countries. Manufacturing facilities are located in the United States, Singapore, Costa Rica and Ireland.
A summary of the business section of the company's latest annual report, filed 25 Feb 2026.
Company facts
| Ticker | EW · NYSE |
|---|
| Sector | Medical devices |
|---|
| Industry | Health Care Equipment |
|---|
| Index | S&P 500 |
|---|
| Fiscal year ends | 31 December |
|---|
| Reporting currency | USD |
|---|
| CIK | 1099800 |
|---|
| Latest annual report | 10-K, filed 25 Feb 2026 |
|---|
Officers and directors
| Name | Role | Shares owned | Latest Form 4 |
|---|
| Dahl Andrew M. | SVP, Corporate Controller | — | Shares withheld for tax, 13 Nov 2026 |
|---|
| Lippis Daniel J. | CVP, TAVR | — | Option exercise, 10 Nov 2026 |
|---|
| Zovighian Bernard J | CEO · Director | — | Option exercise, 9 Nov 2026 |
|---|
| BOBO DONALD E JR | CVP,Strategy/Corp Development | — | Option exercise, 9 Nov 2026 |
|---|
| Markowitz Wayne | CVP, JAPAC | — | Shares withheld for tax, 14 Sep 2026 |
|---|
| Chopra Daveen | CVP, TMTT, Surgical & IHFM | — | Shares withheld for tax, 11 Sep 2026 |
|---|
| Bruls Annette | CVP, EMEACLA | — | Open-market sale, 28 Aug 2026 |
|---|
| Mistras Theodora | CVP, Chief Financial Officer | — | Grant or award, 9 Jul 2026 |
|---|
| Ullem Scott B. | CVP, Chief Financial Officer | — | Option exercise, 11 May 2026 |
|---|
| VALERIANI NICHOLAS J | Director | — | Grant or award, 8 May 2026 |
|---|
| Sequeira Ramona | Director | — | Grant or award, 8 May 2026 |
|---|
| LORANGER STEVEN R | Director | — | Grant or award, 8 May 2026 |
|---|
| LAVIOLETTE PAUL A | Director | — | Grant or award, 8 May 2026 |
|---|
| STONE HEISZ LESLIE | Director | — | Grant or award, 8 May 2026 |
|---|
| GALLAHUE KIERAN | Director | — | Grant or award, 8 May 2026 |
|---|
| Feinberg David T | Director | — | Grant or award, 8 May 2026 |
|---|
| Davis Leslie C. | Director | — | Grant or award, 8 May 2026 |
|---|
| Wood Larry L | Global President TAVR & Surg | — | Option exercise, 18 Aug 2025 |
|---|
Holdings as the latest proxy statement states them, all forms counted; the latest Form 4 line each filed. People appointed since the proxy are listed from their Form 4 filings.
EW in the terminal
The business section of every annual report, officers' holdings and trades, and the company's filings as they arrive.